Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
GD2 expression in breast cancer.
Orsi G, Barbolini M, Ficarra G, Tazzioli G, Manni P, Petrachi T, Mastrolia I, Orvieto E, Spano C, Prapa M, Kaleci S, D'Amico R, Guarneri V, Dieci MV, Cascinu S, Conte P, Piacentini F, Dominici M. Orsi G, et al. Among authors: orvieto e. Oncotarget. 2017 May 9;8(19):31592-31600. doi: 10.18632/oncotarget.16363. Oncotarget. 2017. PMID: 28415563 Free PMC article.
Immune characterization of breast cancer metastases: prognostic implications.
Dieci MV, Tsvetkova V, Orvieto E, Piacentini F, Ficarra G, Griguolo G, Miglietta F, Giarratano T, Omarini C, Bonaguro S, Cappellesso R, Aliberti C, Vernaci G, Giorgi CA, Faggioni G, Tasca G, Conte P, Guarneri V. Dieci MV, et al. Among authors: orvieto e. Breast Cancer Res. 2018 Jun 22;20(1):62. doi: 10.1186/s13058-018-1003-1. Breast Cancer Res. 2018. PMID: 29929548 Free PMC article.
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation.
Carbognin L, Sperduti I, Fabi A, Dieci MV, Kadrija D, Griguolo G, Pilotto S, Guarneri V, Zampiva I, Brunelli M, Orvieto E, Nortilli R, Fiorio E, Parolin V, Manfrin E, Caliò A, Nisticò C, Pellini F, Scarpa A, Pollini GP, Conte P, Tortora G, Bria E. Carbognin L, et al. Among authors: orvieto e. Breast. 2017 Oct;35:21-26. doi: 10.1016/j.breast.2017.06.005. Epub 2017 Jun 17. Breast. 2017. PMID: 28628772
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Dieci MV, Guarneri V, Giarratano T, Mion M, Tortora G, De Rossi C, Gori S, Oliani C, Merlini L, Pasini F, Bonciarelli G, Griguolo G, Orvieto E, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P. Dieci MV, et al. Among authors: orvieto e. Oncologist. 2018 Mar;23(3):297-305. doi: 10.1634/theoncologist.2017-0322. Epub 2017 Nov 13. Oncologist. 2018. PMID: 29133514 Free PMC article.
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV, Guarneri V, Zustovich F, Mion M, Morandi P, Bria E, Merlini L, Bullian P, Oliani C, Gori S, Giarratano T, Orvieto E, Griguolo G, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P; Veneto Oncology Network. Dieci MV, et al. Among authors: orvieto e. Oncologist. 2019 Nov;24(11):1424-1431. doi: 10.1634/theoncologist.2019-0103. Epub 2019 May 31. Oncologist. 2019. PMID: 31152079 Free PMC article.
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV, Tsvetkova V, Griguolo G, Miglietta F, Tasca G, Giorgi CA, Cumerlato E, Massa D, Lo Mele M, Orvieto E, Guarneri V, Conte P. Dieci MV, et al. Among authors: orvieto e. Eur J Cancer. 2020 Sep;136:7-15. doi: 10.1016/j.ejca.2020.05.014. Epub 2020 Jul 1. Eur J Cancer. 2020. PMID: 32622323 Free article.
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype.
Guarneri V, Dieci MV, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Nanni O, Piacentini F, Orvieto E, Griguolo G, Curtarello M, Urso L, Paré L, Chic N, D'Amico R, Prat A, Conte P. Guarneri V, et al. Among authors: orvieto e. Clin Cancer Res. 2020 Nov 15;26(22):5843-5851. doi: 10.1158/1078-0432.CCR-20-1731. Epub 2020 Aug 25. Clin Cancer Res. 2020. PMID: 32843527 Clinical Trial.
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome.
Griguolo G, Dieci MV, Giarratano T, Giorgi CA, Orvieto E, Ghiotto C, Berti F, Della Puppa A, Falci C, Mioranza E, Tasca G, Milite N, Miglietta F, Scienza R, Conte P, Guarneri V. Griguolo G, et al. Among authors: orvieto e. J Neurooncol. 2017 Jan;131(2):369-376. doi: 10.1007/s11060-016-2309-4. Epub 2016 Nov 16. J Neurooncol. 2017. PMID: 27853958
Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?
Evangelista L, Cervino AR, Ghiotto C, Saibene T, Michieletto S, Fernando B, Orvieto E, Guarneri V, Conte P. Evangelista L, et al. Among authors: orvieto e. Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1648-1655. doi: 10.1007/s00259-015-3088-4. Epub 2015 May 31. Eur J Nucl Med Mol Imaging. 2015. PMID: 26025244
68 results